Elevance Health price target lowered to $316 from $428 at Morgan Stanley – TipRanks

Morgan Stanley lowered the firm’s price target on Elevance Health (ELV) to $316 from $428 and keeps an Equal Weight rating on the shares. While reduced 2025 guidance was expected, the lack of clarity into 2026 is “concerning” in light of Medicaid and exchange trend headwinds that “could prove more enduring,” the analyst tells investors in a post-earnings note.

Elevate Your Investing Strategy:

Disclaimer & DisclosureReport an Issue